News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Feb 19, 2014

  Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

  Initial 12-Month Data Demonstrate Long-Term Safety and Durability of Effect
• Feb 10, 2014

  ARIKACE to Receive Orphan Medicinal Product Designation in the European Union to Treat Lung Infections Caused by Nontuberculous Mycobacteria
• Feb 4, 2014

  Insmed to Present at the Leerink Swann Global Healthcare Conference
• Feb 4, 2014

  Insmed to Present at the Leerink Swann Global Healthcare Conference
• Nov 5, 2013

  Insmed Reports Third Quarter 2013 Financial Results
• Nov 1, 2013

  Insmed Appoints David W.J. McGirr to Its Board of Directors
• Oct 23, 2013

  Insmed to Host Third Quarter 2013 Financial Results Conference Call on Tuesday, November 5, 2013
• Oct 15, 2013

  Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada
• Sep 15, 2013

  Insmed to Present at Leerink Swann Rare Disease Roundtable
• Sep 11, 2013

  Insmed Fortifies Global Patent Portfolio

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download